Osseon™ Therapeutics, Inc. Announces New Member to Board of Directors

SANTA ROSA, Calif., Sept. 23 /PRNewswire/ -- Osseon Therapeutics today announced that Robert W. Thomas has joined the company's Board of Directors.  Mr. Thomas brings over 20 years of senior management and Board experience in the medical device industry to the company, and will provide guidance and strategic vision to Osseon's Board and Management Team.

Sidney Lazard, Osseon's Board Chairman, commented that "Mr. Thomas brings extensive experience in management, manufacturing, product strategy, distribution, and acquisition of medical device companies to Osseon's Board.  This is a very important skill-set for the Company and management team at this time.  We are extremely pleased to have his involvement in Osseon."

"We are thrilled to have someone with Mr. Thomas' pedigree on our Board," said John Stalcup, Ph.D., CEO and Board Member. "He has successfully led several medical device companies through rapid growth and expansion, generating significant value to shareholders, employees, and the medical community.  His proven ability to bridge strategy with operational excellence will be invaluable to our team as we continue our product development, expand our relationships with healthcare providers, and build our market presence."

Mr. Thomas currently serves as a member of the Board of Directors for numerous companies in the life sciences field.  Prior to his Board work, Mr. Thomas served from 1999 until 2006 as Vice President of Operations, President and CEO, and Board member of Fox Hollow Technologies, an endovascular device success story. As the CEO of Fox Hollow, Mr. Thomas led the company of 12 employees in startup mode through a successful public offering with over $1 billion in market capitalization.  From 1998 through 1999, Mr. Thomas served as Vice-President of Operations for Conceptus, a leading innovator of medical devices in women's health.  Prior to Conceptus, Mr. Thomas was a founder of TMP, Inc, a privately financed medical device start-up company in Malvern, PA, which was acquired by VSI (now GE Healthcare) in 1992.  From 1984 through 1990, Mr. Thomas was a Founder and held various managerial positions with Access Devices (acquired by Baxter Healthcare) in Bristol, PA.  Mr. Thomas received a B.A. in Economics from Ursinus College.

According to Mr. Thomas, "Osseon is on the path of addressing an expanding market in the treatment of vertebral compression fractures (VCF) and other muscular-skeletal and metastatic diseases resulting from osteoporosis, osteo-traumatic injuries, and cancer.  The company is extremely well positioned to become a market leader in innovative treatments for VCFs and other debilitating maladies. I am looking forward to working with the Board and Management Team and taking Osseon to the next level of organizational growth and development."

ABOUT Osseon Therapeutics, Inc.

About Osseon

Osseon Therapeutics, Inc. focuses on bringing to market alternative minimally invasive treatments for degenerative bone and joint disease.  Headquartered in Santa Rosa, CA, the company's groundbreaking technology and delivery system provides comparable or better efficacy and safety than other commercial solutions while offering significant advantages in efficiency and cost. By improving the treatment of compression fractures within the thoracic and lumbar vertebral spine, Osseon offers alternative solutions to patients suffering from these maladies, as well as the physicians and medical facilities that treat them.  Its first-generation products have received both FDA clearance and the CE Mark for product distribution in the United States and European Union. For more information, visit our web site at www.osseon.com.

Osseon™ is a registered trademark of Osseon Therapeutics,  Inc. The names of actual companies and products mentioned herein may be the trademarks of their respective owners.

SOURCE Osseon Therapeutics, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED